Skip Menu

Core B: Biosafety Level 4 (BSL-4) Core

Core Lead: Alexander Bukreyev, PhD (University of Texas Medical Branch)
Co-Investigator: Thomas W. Geisbert, PhD (University of Texas Medical Branch)

Core B

The procedures that will be performed in Core B are critical for achieving the major goals of the proposed studies, including: (a) detailed knowledge of transcriptional mechanisms leading to the dysregulated immune response to EBOV, (b) elucidation of the role of posttranscriptional mechanisms in the dysregulated immune response to EBOV, (c) elucidation of the role of posttranslational mechanisms in the dysregulated immune response to EBOV, and (d) building and experimental validation of a comprehensive model for the pathogenesis of EBOV infection and other severe viral infections, such as Marburg, Lassa fever, dengue, and COVID-19. Completion of Core B Specific Aims will provide critical support for RP1, RP2, and RP3 to identify the role of transcriptional, posttranscriptional, and posttranslational mechanisms in the dysregulated immune response to EBOV.

Alexander Bukreyev

The Program Proposal is aimed at identification of epigenetic and post-transcriptional mechanisms leading to dysregulated immune response to Ebola virus. Dr. Bukreyev will oversee the planning and coordination of the BSL-4 Core to work in tandem with the rest of the research program.

Bukreyev Lab

Website: Bukreyev Lab website
Lab Phone: (409) 772-2831

Thomas Geisbert

Dr. Geisbert has extensive experience in developing and refining appropriate pre-clinical models that mimic human disease, including the research model used in this project. He will oversee all aspects of the BSL-4 pre-clinical studies.

Thomas Geisbert Lab (UTMB)